Wnt/beta-catenin signaling in cancer stemness and malignant behavior - PubMed (original) (raw)
Review
Wnt/beta-catenin signaling in cancer stemness and malignant behavior
Riccardo Fodde et al. Curr Opin Cell Biol. 2007 Apr.
Abstract
Stem cells are defined by their intrinsic capacity to self-renew and differentiate. Cancer stem cells retain both these features but have lost homeostatic mechanisms which maintain normal cell numbers. The canonical Wnt/beta-catenin signaling pathway plays a central role in modulating the delicate balance between stemness and differentiation in several adult stem cell niches such as the hair follicles in the skin, the mammary gland, and the intestinal crypt. Accordingly, constitutive Wnt signaling activation, resulting from mutations in genes encoding its downstream components, underlies tumorigenesis in these tissues. In the majority of sporadic colorectal cancer cases, the rate-limiting event is either loss of APC function or oncogenic beta-catenin mutations. However, although the presence of these initiating mutations would predict nuclear beta-catenin accumulation throughout the tumor mass, heterogeneous intracellular distributions of this key Wnt signaling molecule are observed within primary tumors and their metastases. In particular, tumor cells located at the invasive front and those migrating into the adjacent stromal tissues show nuclear beta-catenin staining. Hence, different levels of Wnt signaling activity reflect tumor heterogeneity and are likely to account for distinct cellular activities such as proliferation and epithelial-mesenchymal transitions, which prompt tumor growth and malignant behavior, respectively. Several intrinsic (cell-autonomous and/or autocrine) and extrinsic (paracrine, derived from the tumor microenvironment) factors may explain this heterogeneity of Wnt/beta-catenin signaling activity within the tumor mass.
Similar articles
- APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression.
Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, Rosty C, Abal M, El Marjou F, Smits R, Louvard D, Fodde R, Robine S. Janssen KP, et al. Gastroenterology. 2006 Oct;131(4):1096-109. doi: 10.1053/j.gastro.2006.08.011. Epub 2006 Aug 16. Gastroenterology. 2006. PMID: 17030180 - Wnt pathway mutations selected by optimal beta-catenin signaling for tumorigenesis.
Cho KH, Baek S, Sung MH. Cho KH, et al. FEBS Lett. 2006 Jun 26;580(15):3665-70. doi: 10.1016/j.febslet.2006.05.053. Epub 2006 Jun 5. FEBS Lett. 2006. PMID: 16764864 - Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.
Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. Hendrix ND, et al. Cancer Res. 2006 Feb 1;66(3):1354-62. doi: 10.1158/0008-5472.CAN-05-3694. Cancer Res. 2006. PMID: 16452189 - Targeting Wnt signaling: can we safely eradicate cancer stem cells?
Takahashi-Yanaga F, Kahn M. Takahashi-Yanaga F, et al. Clin Cancer Res. 2010 Jun 15;16(12):3153-62. doi: 10.1158/1078-0432.CCR-09-2943. Epub 2010 Jun 8. Clin Cancer Res. 2010. PMID: 20530697 Review. - Wnt signaling pathway in mammary gland development and carcinogenesis.
Turashvili G, Bouchal J, Burkadze G, Kolar Z. Turashvili G, et al. Pathobiology. 2006;73(5):213-23. doi: 10.1159/000098207. Pathobiology. 2006. PMID: 17314492 Review.
Cited by
- Differential Regulation of Wingless-Wnt/c-Jun N-Terminal Kinase Crosstalk via Oxidative Eustress in Primary and Metastatic Colorectal Cancer Cells.
Aceto GM, Pagotto S, Del Pizzo FD, Saoca C, Selvaggi F, Visone R, Cotellese R, Aguennouz M, Lattanzio R, Catalano T. Aceto GM, et al. Biomedicines. 2024 Aug 9;12(8):1816. doi: 10.3390/biomedicines12081816. Biomedicines. 2024. PMID: 39200280 Free PMC article. - High Serum Levels of CCL20 Are Associated with Recurrence and Unfavorable Overall Survival in Advanced Melanoma Patients Receiving Immunotherapy.
Kött J, Hoehne IL, Heidrich I, Zimmermann N, Reese KL, Zell T, Geidel G, Rünger A, Schneider SW, Pantel K, Smit DJ, Gebhardt C. Kött J, et al. Cancers (Basel). 2024 Apr 29;16(9):1737. doi: 10.3390/cancers16091737. Cancers (Basel). 2024. PMID: 38730689 Free PMC article. - Significant Genes Associated with Mortality and Disease Progression in Grade II and III Glioma.
Choi BM, Cheong JH, Ryu JI, Won YD, Min KW, Han MH. Choi BM, et al. Biomedicines. 2024 Apr 12;12(4):858. doi: 10.3390/biomedicines12040858. Biomedicines. 2024. PMID: 38672212 Free PMC article. - Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance.
Bhat GR, Sethi I, Sadida HQ, Rah B, Mir R, Algehainy N, Albalawi IA, Masoodi T, Subbaraj GK, Jamal F, Singh M, Kumar R, Macha MA, Uddin S, Akil ASA, Haris M, Bhat AA. Bhat GR, et al. Cancer Metastasis Rev. 2024 Mar;43(1):197-228. doi: 10.1007/s10555-024-10172-z. Epub 2024 Feb 8. Cancer Metastasis Rev. 2024. PMID: 38329598 Free PMC article. Review. - Elucidating the Role of Pro-renin Receptors in Pancreatic Ductal Adenocarcinoma Progression: A Novel Therapeutic Target in Cancer Therapy.
Aliakbarian M, Ferns GA, Shabestari MM, Ahmadzadeh AM, Abdollahzade A, Rahimi H, Khodashahi R, Arjmand MH. Aliakbarian M, et al. Curr Cancer Drug Targets. 2024;24(9):881-889. doi: 10.2174/0115680096279288231205105904. Curr Cancer Drug Targets. 2024. PMID: 38279719 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources